Chapter 20: Cancer: Molecular Basis & Cellular Transformation

Cancer: Molecular Basis & Cellular Transformation begins by distinguishing between benign growths that remain localized and malignant tumors—properly called cancers—that are capable of invasive behavior and metastasis through the body's circulatory or lymphatic systems. The progression of cancer is framed as a complex, multistep evolutionary process where accumulated genetic alterations in single progenitor cells lead to clonal selection for increasingly aggressive cell populations with high levels of genetic instability. Key hallmarks of these malignant cells include the loss of contact inhibition, the independent production of growth factors through autocrine stimulation, the secretion of proteases to breach tissue barriers, the induction of new blood vessel formation via angiogenesis, and the activation of telomerase for unlimited replicative potential. The text explores the fundamental triggers of carcinogenesis, ranging from chemical carcinogens and radiation that induce DNA mutations to tumor viruses that introduce new genetic material into host cells. A significant focus is placed on oncogenes, which are mutated or overexpressed forms of normal cellular proto-oncogenes that drive signaling pathways, such as the Ras-Raf-ERK cascade, to permanently switch on signals for division. Conversely, the role of tumor suppressor genes is detailed, specifically how the inactivation of negative regulators like Rb and p53 removes critical checkpoints for cell cycle arrest and programmed cell death (apoptosis). The chapter also addresses genome stability genes, such as BRCA1 and BRCA2, whose failure increases the overall frequency of mutations across the genome. Finally, modern molecular approaches to oncology are discussed, highlighting the shift toward highly selective targeted therapies—such as small molecule inhibitors like imatinib and monoclonal antibodies like Herceptin—alongside revolutionary immunotherapies including checkpoint inhibitors and the genetic engineering of CAR-T cells to bolster the body's natural defenses.